| Sumario: | BACKGROUND According to The European Society of Cardiology (ESC) Guidelines, despite the implementation of the most effective heart failure (HF) therapies, HF is a growing clinical problem. Many patients (pts) do not receive optimal, the most effective treatment. AIM Evaluation of the implementation of HF treatment on admission and during hospital discharge or outpatient consultation in Polish population. MATERIAL AND METHODS The HEart FailuRe ObsErvational Study (HEROES) of the Polish Society of Cardiology was a prospective, multicenter ob-servational project. 1174 consecutive pts (73.5 % males), with HF (previously or currently diagnosed and treated, in the outpatient or hospital care), were included in the study, who reported to cardiac centers from April 2022 to June 2023. Clinical data and applied therapy were collected at the time of inclusion in the project and at discharge or consultation. RESULTS The mean age of pts was 64.77 ± 15.53 years old. At the enrolment time, the average N-terminal prohormone of brain natriuretic peptide (NTproBNP) level was 5938.9 pg/ml, average left ventricle ejection fraction (LVEF) was 38.27%. Heart failure treatment at admission and at discharge or consultation is presented in Table 1. SUMMARY HF is a very severe condition which may increase the mortality level. In the whole project pts were mainly treated with beta-blockers (BB), diuretics, ACEI and MRA. At the time of inclusion BB and diuretics were preferable. During discharge the role of BB and single diuretics was clinically significant. ARNI and ARB were used the least. At the time of discharge or outpatient consultation the use of ARNI, ACEI, MRA, BB, SGLT2i, has increased. Early and adequate treatment initiation may reduce the HF consequences.
|
|---|